MedTrace Logo

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

NCT04653480 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2023-07-17

No results posted yet for this study

Summary

To determine the efficacy and safety of surufatinib, toripalimab and chemotherapy in second-line RAS/BRAF mutant and MSS colorectal cancer

Conditions

Interventions

DRUG

Surufatinib

250mg per oral, once daily

DRUG

Toripalimab

3mg/kg IV, once every 2 weeks

DRUG

chemotherapy

oxaliplatin or irinotecan based regimens, according to the first line treatment

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04653480 on ClinicalTrials.gov